Recent approaches to H. pylori eradication highlight probiotics as a key adjunct during eradication therapy. Clinical evidence indicates that probiotic supplementation is associated with improved eradication rates and a reduction in overall treatment related adverse effects during standard therapy. Notably, enhanced outcomes have been observed with higher probiotic doses (100 × 10⁹ CFU) and the use of multi strain formulations.

Pylopass™ is a heat-inactivated bacterial strain, Lactobacillus reuteri DSM 17648, patented for its unique benefits in the management of H. pylori infection. It contains specific surface structures that recognize and bind to H. pylori, forming co-aggregates. These aggregates not only inhibit the adhesion of free H. pylori cells but also facilitate the removal of bacteria that have already colonized the gastric mucosa.

Adjunctive use of Pylopass™ alongside standard antibiotic therapy has been associated with near-complete eradication of H. pylori, with reported success rates reaching up to 96.7%.

The postbiotic Lactobacillus rhamnosus CRL1505™ supports the host immune response and contributes to the reduction of symptoms associated with infection by Helicobacter pylori.